Q2 FY2026 EarningsQ2 FY26 results presented a significant variance between operational performance and GAAP outcomes. While the loss from operations of $3.5M was favorable compared to the $4.5M EBIT loss consensus, GAAP net loss of $7.07M missed the $4.36M expectation by over 62%. This discrepancy was driven entirely by non-cash warrant-related charges totaling $3.6M following the May 2026 offering. The company issued a 'going concern' warning, noting that existing liquidity of $7.36M is insufficient for the next 12 months.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Lantern Pharma(LTRN) the EBIT is -3.508 M (+24.59%), Beat estimate;the EPS is -0.57 (-42.5%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.00B24.59%
-0.00B3.27%
+0.00B21.32%
EPSMiss expectations
-0.5742.50%
-0.385.00%
-0.190047.50%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf